Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.650
-0.060 (-3.51%)
Aug 29, 2025, 4:00 PM - Market closed

Company Description

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.

Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors.

The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics logo
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees28
CEOEric Poma

Contact Details

Address:
4475 Executive Drive, Suite 200
San Diego, California 92121
United States
Phone858 794 9600
Websitecalidibio.com

Stock Details

Ticker SymbolCLDI
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001855485
CUSIP Number320703309
ISIN NumberUS3207033099
Employer ID86-2967193
SIC Code2836

Key Executives

NamePosition
Dr. Eric E. Poma Ph.D.Chief Executive Officer and Director
Andrew C. JacksonChief Financial Officer
Wendy Pizarro Campbell Esq.Chief Legal, Chief Corporate Dev, Chief Diversity and Corp Secretary
Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D.Head of Technical Operations and Chief Scientific Officer
Dr. Guy Travis Clifton M.D.Chief Medical Officer, Consultant and Advisor

Latest SEC Filings

DateTypeTitle
Aug 29, 20258-KCurrent Report
Aug 27, 2025SCHEDULE 13GFiling
Aug 22, 20258-KCurrent Report
Aug 21, 2025424B4Prospectus
Aug 20, 2025EFFECTNotice of Effectiveness
Aug 15, 2025S-1General form for registration of securities under the Securities Act of 1933
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 14, 20258-KCurrent Report
Aug 8, 202510-QQuarterly Report
Aug 8, 20258-KCurrent Report